Irish Journal of Medical Science

, Volume 156, Issue 8, pp 236–237 | Cite as

The response of the normochromic normocytic anaemia of chronic renal failure to Desferrioxamine

  • A. A. J. O’Brien
  • D. P. Moore
  • J. A. B. Keogh


Five patients with chronic renal failure on haemodialysis with the normochromic normocytic anaemia of chronic renal failure, were treated with Desferrioxamine 40 mgs/Kg/week, over a period of three months for aluminium osteodystrophy. The mean haemoglobin rise was 2.5±0.3 grams% (P< 0.05). The haematocrit rose by 9±2.5% (P< 0.05). The mean ±s.e.m. M.C.V. rise was 5±0.85 Fl (P< 0.001) and the mean ±s.e.m. M.C.H. rise was 2.5±0.28 (P< 0.001). The red blood cell and M.C.H.C. did not show a significant rise. Serum Ferritin levels were raised with a mean of 1500±350 and fell by 500±150 (P< 0.001). The transfusion requirement of the five patients (previously 10 units per month) fell to 2 units per month over the same period. The renal indices did not show a significant change.


Chronic Renal Failure Transfusion Requirement Serum Ferritin Level Desferrioxamine Haematological Index 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Elliott, H. L., Dryburgh, F., Fell, G. S. et al. Aluminium toxicity during regular haemodialysis. Br. Med. J. 1978: 1101–1103.Google Scholar
  2. 2.
    O’Hare, J. A., Murnaghan, D. J. Reversal of aluminium-induced haemodialysis anaemia by low-aluminium dialysate. N. Engl. J. Med. 1982: 306, 654–656.PubMedGoogle Scholar
  3. 3.
    Kaiser, L., Schwartz, K. A., Burnatowska Hledin, M. A. et al. Microcytic anaemia secondary to intraperitoneal aluminium in normal and uraemic rats. Kidney Int. 1986: 26, 269–274.CrossRefGoogle Scholar
  4. 4.
    Meredith, P. A., Moore, M. R., Goldbert, A. The effects of aluminium, lead and zinc on delta-amino laevulinic acid dehydratase. Biochem. Soc. Trans. 1974: 1243–1245.Google Scholar
  5. 5.
    Praga, M., Andres, A., Nieto, J. et al. Desferrioxamine (DFO) improves the anaemia of haemodialysis patients without aluminium (AL) intoxication. Proc. EDTA 1986: 23, 64 (abstract).Google Scholar
  6. 6.
    Tielemans, C., Collart, F., Wens, R. et al. Improvement of anaemia with deferoxamine in haemodialysis patients with aluminium-induced bone disease. Clin. Nephrol. 1985: 24, 237–241.PubMedGoogle Scholar

Copyright information

© Springer 1987

Authors and Affiliations

  • A. A. J. O’Brien
    • 1
  • D. P. Moore
    • 1
  • J. A. B. Keogh
    • 1
  1. 1.Department of Clinical MedicineMeath HospitalDublin 8

Personalised recommendations